Drugs / NN3201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06805825 | Feb 2025 → Aug 2027 expected | adenoid cystic carcinoma, chromophobe renal cell carcinoma, clear cell renal carcinoma, gastrointestinal stromal tumor +2 | Novelty Nobility, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NN3201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06805825 ↗ |
| Modality | Monoclonal antibody | “a c-Kit targeting fully human monoclonal antibody-drug conjugate” NCT06805825 ↗ |
| Route | Intravenous | “administered by IV” NCT06805825 ↗ |